EKF DIAGNOSTICS HOLDINGS PLC Financials EKF Diagnostics Holdings plc
Equities
EKF
GB0031509804
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.6 GBX | -0.72% |
|
+0.73% | -12.80% |
| Apr. 11 | Onward Opportunities' small-cap strategy yields solid results in 2023 | AN |
| Mar. 20 | EKF Diagnostics says prospects "promising" but pauses dividends | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 124 | 155.5 | 326.5 | 347.9 | 227.5 | 125.2 | 125.2 | - |
| Enterprise Value (EV) 1 | 114.6 | 145.1 | 306.1 | 328.3 | 216 | 140 | 115.5 | 108.1 |
| P/E ratio | 12.5 x | - | 29.6 x | 21.8 x | -22.6 x | 60.9 x | 29.4 x | 20.4 x |
| Yield | - | 2.92% | 1.53% | 1.6% | 2.4% | 3.79% | 4.35% | 4.89% |
| Capitalization / Revenue | 2.91 x | 3.46 x | 5 x | 4.25 x | 3.41 x | 2.73 x | 2.26 x | 2.09 x |
| EV / Revenue | 2.69 x | 3.23 x | 4.69 x | 4.01 x | 3.24 x | 2.66 x | 2.08 x | 1.8 x |
| EV / EBITDA | 10.7 x | 12.1 x | 12 x | 12.4 x | 14.5 x | 13.5 x | 9.89 x | 7.84 x |
| EV / FCF | - | - | 25.1 x | 55.6 x | 56 x | -211 x | 14 x | 13.7 x |
| FCF Yield | - | - | 3.98% | 1.8% | 1.79% | -0.47% | 7.13% | 7.32% |
| Price to Book | 1.96 x | 2.22 x | 4.22 x | 3.64 x | 3.1 x | 1.86 x | 1.83 x | 1.83 x |
| Nbr of stocks (in thousands) | 454,093 | 454,093 | 454,993 | 463,931 | 454,931 | 453,731 | 453,731 | - |
| Reference price 2 | 0.2730 | 0.3425 | 0.7175 | 0.7500 | 0.5000 | 0.2760 | 0.2760 | 0.2760 |
| Announcement Date | 3/13/19 | 4/7/20 | 3/30/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.54 | 44.92 | 65.26 | 81.84 | 66.64 | 52.61 | 55.49 | 59.96 |
| EBITDA 1 | 10.68 | 12 | 25.52 | 26.49 | 14.9 | 10.38 | 11.68 | 13.78 |
| EBIT 1 | 8.578 | 8.375 | 18.38 | 25.69 | 12.11 | 7.11 | 6.638 | 8.286 |
| Operating Margin | 20.16% | 18.65% | 28.16% | 31.39% | 18.18% | 13.51% | 11.96% | 13.82% |
| Earnings before Tax (EBT) 1 | 12.16 | - | 15.36 | 21.44 | -8.942 | 2.131 | 6.63 | 9 |
| Net income 1 | 10.11 | - | 11.11 | 15.85 | -10.1 | 2.352 | 3.99 | 5.87 |
| Net margin | 23.76% | - | 17.03% | 19.37% | -15.16% | 4.47% | 7.19% | 9.79% |
| EPS 2 | 0.0219 | - | 0.0242 | 0.0344 | -0.0221 | 0.005200 | 0.009400 | 0.0135 |
| Free Cash Flow 1 | - | - | 12.18 | 5.903 | 3.86 | -0.664 | 8.232 | 7.917 |
| FCF margin | - | - | 18.66% | 7.21% | 5.79% | -1.26% | 14.84% | 13.2% |
| FCF Conversion (EBITDA) | - | - | 47.73% | 22.28% | 25.9% | - | 70.5% | 57.44% |
| FCF Conversion (Net income) | - | - | 109.57% | 37.24% | - | - | 206.32% | 134.88% |
| Dividend per Share 2 | - | 0.0100 | 0.0110 | 0.0120 | 0.0120 | 0.0120 | 0.0120 | 0.0135 |
| Announcement Date | 3/13/19 | 4/7/20 | 3/30/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.44 | 23.48 | 26.33 | 38.93 | 38.56 | 43.28 | 37.47 | 29.16 | 26.87 | 25.74 | 26.04 | 28.18 |
| EBITDA 1 | 5.584 | 6.421 | 8.925 | 16.59 | 12.76 | 13.73 | 9.711 | 5.193 | 4.416 | 5.968 | 5.01 | 6.63 |
| EBIT 1 | 3.655 | - | 7.753 | 10.63 | 10.45 | 12.45 | 6.35 | 4.425 | 3.497 | 4.285 | 3.32 | 4.93 |
| Operating Margin | 17.05% | - | 29.45% | 27.3% | 27.1% | 28.77% | 16.95% | 15.17% | 13.01% | 16.65% | 12.75% | 17.49% |
| Earnings before Tax (EBT) 1 | 2.226 | - | 6.249 | 9.107 | 11.42 | 10.01 | 4.14 | -13.08 | -0.026 | 2.157 | 2.25 | 4.38 |
| Net income 1 | 1.326 | - | 4.011 | 7.103 | 9.069 | 6.782 | 2.213 | -12.31 | -0.358 | 2.71 | 1.3 | 2.69 |
| Net margin | 6.19% | - | 15.23% | 18.25% | 23.52% | 15.67% | 5.91% | -42.22% | -1.33% | 10.53% | 4.99% | 9.55% |
| EPS 2 | 0.002900 | - | 0.008700 | 0.0155 | 0.0198 | 0.0146 | 0.004800 | -0.0269 | -0.000800 | 0.006000 | 0.002900 | 0.006500 |
| Dividend per Share 2 | - | 0.0100 | - | 0.0110 | - | 0.0120 | - | 0.0120 | - | 0.0120 | - | - |
| Announcement Date | 9/10/19 | 4/7/20 | 9/14/20 | 3/30/21 | 9/14/21 | 3/29/22 | 9/20/22 | 3/28/23 | 9/26/23 | 3/20/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 9.4 | 10.4 | 20.3 | 19.6 | 11.4 | 3.63 | 9.78 | 17.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 12.2 | 5.9 | 3.86 | -0.66 | 8.23 | 7.92 |
| ROE (net income / shareholders' equity) | - | - | - | 18.5% | -11.3% | 7.38% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.1400 | 0.1500 | 0.1700 | 0.2100 | 0.1600 | 0.1500 | 0.1500 | 0.1500 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0300 | 0.0200 | 0.0200 | 0.0100 | 0.0100 | 0.0200 |
| Capex 1 | 1.22 | 1.42 | 1.63 | 4.34 | 4.43 | 6.6 | 3.15 | 3 |
| Capex / Sales | 2.87% | 3.16% | 2.5% | 5.3% | 6.65% | 12.54% | 5.68% | 5% |
| Announcement Date | 3/13/19 | 4/7/20 | 3/30/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.276
GBP
Average target price
0.3333
GBP
Spread / Average Target
+20.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.80% | 156M | |
| +4.55% | 3.48B | |
| -15.69% | 81.85M | |
| +30.43% | 59.71M |
- Stock Market
- Equities
- EKF Stock
- Financials EKF Diagnostics Holdings plc
